William Blair upgraded Genmab (GMAB) to Outperform from Market Perform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Expectations for J&J Genmab opt-in lowered ahead of news, says Morgan Stanley
- JPMorgan expects ‘significant’ underperformance of Genmab shares
- Genmab’s HexaBody-CD38 Development Halted After J&J Decision
- Genmab says J&J not exercising option on HexaBody-CD38
- Genmab falls 7% to $22.44 after J&J declines option on HexaBody-CD38